Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$194.29 USD

194.29
3,606,158

-1.16 (-0.59%)

Updated Oct 4, 2024 03:59 PM ET

After-Market: $193.90 -0.39 (-0.20%) 7:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Mark Vickery headshot

Top Analyst Reports for Walmart, AbbVie & Nike

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Walmart Inc. (WMT), AbbVie Inc. (ABBV) and Nike, Inc. (NKE).

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, AbbVie (ABBV) closed at $133.59, marking a -1.03% move from the previous day.

Is WisdomTree U.S. High Dividend ETF (DHS) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for DHS

Incyte's (INCY) Opzelura Meets Goal in Phase III Pediatric Study

by Zacks Equity Research

Incyte's (INCY) Opzelura (ruxolitinib cream) meets the primary endpoint in a phase III study in children with atopic dermatitis.

Novo Nordisk (NVO) Falls on EMA Safety Review of Obesity Drugs

by Zacks Equity Research

Novo Nordisk's (NVO) important diabetes care and obesity drugs are under review by the EMA's safety committee for the risk of suicidal behavior with its use. The stock falls 3%.

Should You Invest in the Vanguard Health Care ETF (VHT)?

by Zacks Equity Research

Sector ETF report for VHT

Roche (RHHBY) Blood Cancer Drug Columvi Wins EC Approval

by Zacks Equity Research

Roche's (RHHBY) blood cancer portfolio gets a boost with the EC's approval of Columvi (glofitamab-gxbm) for treating patients with R/R DLBCL.

Bausch Health (BHC) Secures $600M Financing Facility, Stock Up

by Zacks Equity Research

Bausch (BHC) enters into a $600 million non-recourse financing facility with KKR to boost liquidity.

Novartis (NVS) Entresto Patent Faces Setback, Stock Down

by Zacks Equity Research

Novartis (NVS) faces a setback in the patent litigation with respect to the blockbuster heart disease drug Entresto. Shares decline.

Zacks.com featured highlights include Dillard's, Suzano, Atkore, Nexstar Media Group and AbbVie

by Zacks Equity Research

Dillard's, Suzano, Atkore, Nexstar Media Group and AbbVie are part of the Zacks Screen of the Week article.

Supriyo Bose headshot

Buy 5 High ROE Stocks as Market Rally Skids on ADP Jobs Data

by Supriyo Bose

Dillard's (DDS), Suzano (SUZ), Atkore (ATKR), Nexstar (NXST) and AbbVie (ABBV) are some of the stocks with high ROE to profit from as markets decline on better-than-expected ADP jobs data.

AbbVie (ABBV) Stock Moves -0.27%: What You Should Know

by Zacks Equity Research

AbbVie (ABBV) closed the most recent trading day at $137.25, moving -0.27% from the previous trading session.

Sarepta (SRPT) Sells Priority Review Voucher for $102M

by Zacks Equity Research

Sarepta (SRPT) sells its priority review voucher that was awarded following the FDA's approval to Elevidys gene therapy for treating DMD. The company will invest these proceeds into R&D.

AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

AstraZeneca (AZN) Down 9% on Mixed Lung Cancer Study Results

by Zacks Equity Research

While AstraZeneca's (AZN) late-stage study evaluating an experimental lung cancer treatment showed improvement in progression free survival, it did not meet the threshold for statistical significance in overall survival.

Novartis (NVS) to Divest Xiidra, SAF312 to Streamline Focus

by Zacks Equity Research

Novartis (NVS) signs a deal to divest Xiidra and SAF312 (libvatrep) to Bausch + Lomb for $2.5 billion.

BioMarin (BMRN) Gets FDA Nod for Hemophilia A Gene Therapy

by Zacks Equity Research

Following FDA's approval, BioMarin's (BMRN) Roctavian becomes the first gene therapy for treating severe hemophilia A.

Sigilon (SGTX) Skyrockets 441% on Buyout Offer From Eli Lilly

by Zacks Equity Research

Eli Lilly (LLY) is set to acquire Sigilon (SGTX) for $14.92 per share, in cash, along with a contingent value right of $111.64 per share.

Ethan Feller headshot

3 Dividend Kings Yielding Royal Sums

by Ethan Feller

Dividend Kings are stocks that have raised their dividends for at least 50 consecutive years

The Zacks Analyst Blog Highlights Novo Nordisk, Home Depot, Disney, AbbVie and Automatic Data Processing

by Zacks Equity Research

Novo Nordisk, Home Depot, Disney, AbbVie and Automatic Data Processing are included in this Analyst Blog.

Sheraz Mian headshot

Top Stock Reports for Novo Nordisk, Home Depot & Walt Disney

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), The Home Depot, Inc. (HD) and The Walt Disney Company (DIS).

Is Global X SuperDividend U.S. ETF (DIV) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for DIV

AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

AbbVie (ABBV) closed the most recent trading day at $134.95, moving -0.71% from the previous trading session.

AbbVie (ABBV) Gets CHMP Positive Opinion for Atogepant Approval

by Zacks Equity Research

AbbVie (ABBV) receives a positive recommendation from the European Union's medicinal products committee for the approval of its migraine treatment candidate, atogepant.